What question did this study set out to answer?

To identify clinical and biological prognostic factors associated with achieving a stable deep molecular response (MR4.5) in patients with chronic myeloid leukemia treated with first-line imatinib.

December 26, 2017OncotargetOpen Access

Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib

View Full Paper

Ask AI

Bookmark

Authors

MBMassimo BrecciaSapienza University of Rome MMMatteo MolicaThe University of Texas MD Anderson Cancer Center GCGioia ColafigliPoliclinico Umberto I

Discussion

Member takes

Implication

Cohort study reveals predictors of stable deep molecular response in chronic myeloid leukemia, highlighting key clinical and biological features for safe treatment discontinuation.

Key Points

To identify clinical and biological prognostic factors associated with achieving a stable deep molecular response (MR4.5) in patients with chronic myeloid leukemia treated with first-line imatinib.
Retrospective cohort analysis of 208 patients with chronic myeloid leukemia receiving first-line imatinib outside clinical trials, followed for a median duration of 7 years.
Stable MR4.5 was defined as BCR-ABL/ABL ≤ 0.0032% on the International Scale confirmed across two or more consecutive assessments.
Prognostic variables were evaluated using univariate analysis and multivariate Cox proportional hazards regression models.
Stable MR4.5 was achieved by 34.6% of patients with a median time to response of 5.4 years.
Multivariate analysis showed stable MR4.5 was independently predicted by female sex (HR 1.6, 95% CI: 1.1–2.6; P = 0.022), Sokal risk score (HR 1.4, 95% CI: 1.1–2.3; P = 0.03), and e14a2 versus e13a2 transcript type (HR 1.6, 95% CI: 1.3–2.9; P = 0.03).
Achievement of early molecular response at 3 months significantly predicted stable deep molecular response in multivariate analysis (HR 1.5, 95% CI: 1.2–2.8; P = 0.01).

Cite This Study

Breccia et al. (2017) studied this question.

synapsesocial.com/papers/6a9b503772bdcf536b47e5aa https://doi.org/10.18632/oncotarget.23691

View Full Paper

Ask AI

Bookmark

Implication

Cohort study reveals predictors of stable deep molecular response in chronic myeloid leukemia, highlighting key clinical and biological features for safe treatment discontinuation.

Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib

Discussion

Member takes

Implication

Key Points

Cite This Study

Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider